Skip to the worksheet
Revision Library
Choose a subject

The Control of Gene Expression - Worksheets, Questions and Revision

17 original exam-style questions - 12 pages of questions with a full mark scheme - free printable PDF.

This topic is chapter 8 of A Level Biology Topic Workbook and chapter 8 of A Level Biology 10-Minute Tests.

Revision Library
revisionlibrary.co.uk
A-Level · Biology

1.8 The Control of Gene Expression

AQA 7402 · Calculator allowed · about 195 minutes
Total Marks
Name: _______________________________    Date: ____ / ____ / ______
Answer ALL questions. Show all your working.
1
Gene mutations occur when the base sequence of DNA is changed.
(a)A single base substitution changes one DNA triplet but, because of the degenerate nature of the genetic code, the amino acid coded for does not change. Which term correctly describes this type of mutation?(1)
  • A) Nonsense mutation
  • B) Silent mutation
  • C) Frameshift mutation
  • D) Missense mutation
(b)Explain why a base deletion is more likely than a single base substitution to have a significant effect on the polypeptide produced.(3)
(c)State one reason why a mutation occurring within an intron is unlikely to affect the amino acid sequence of the final protein.(1)
(Total for Question 1 is 5 marks)
2
Mutations in coding sequences can alter protein products.
(a)Define a missense mutation and a nonsense mutation in coding DNA. One sentence each.(2)
(b)A coding sequence has 900 nucleotides. A single base substitution introduces a stop codon at nucleotide position 601 (counting from the first base of the start codon). How many amino acids long is the truncated protein? Show working.(2)
(Total for Question 2 is 4 marks)
3
Compare repressible and inducible operons in prokaryotes.
(Total for Question 3 is 4 marks)
4
Epigenetics refers to heritable changes in gene expression that occur without a change in the base sequence of DNA. Two epigenetic mechanisms are DNA methylation and histone modification.
(a)Define the term "epigenetics".(1)
(b)Describe how increased methylation of DNA can silence a gene.(3)
(c)Acetylation of histone proteins generally increases the rate of transcription of associated genes. Explain how this occurs.(3)
(d)During development, cells with an identical genome become specialised into different cell types (differentiation). Explain how epigenetic mechanisms allow this to happen.(2)
(Total for Question 4 is 9 marks)
5
This question is based on a core practical technique used in genetic profiling. Restriction enzymes were used to cut DNA samples into fragments, which were then separated using gel electrophoresis. Because the relationship between fragment size and migration distance is not linear, a calibration graph is produced by plotting log10(fragment size in base pairs, bp) against migration distance (mm) for DNA fragments of known size. Two calibration points obtained were: a 100 bp fragment migrated 52 mm, and a 1000 bp fragment migrated 18 mm.
(a)Describe how DNA fragments are separated by gel electrophoresis, referring to charge and size.(2)
(b)Show that the gradient of the calibration line, plotting log10(size/bp) against migration distance (mm), is -0.0294 (to 3 significant figures), using the two calibration points given.(2)
(c)Calculate the size, in bp, of an unknown DNA fragment that migrated 40 mm on the same gel. Give your answer to 3 significant figures.(3)
(d)Explain why, when comparing DNA fingerprints from two different samples, both samples must be cut using the same restriction enzyme before electrophoresis.(2)
(Total for Question 5 is 9 marks)
6
Small interfering RNA (siRNA) is a short, double-stranded RNA molecule that can be used to control the expression of specific genes.
(a)State what is meant by "gene silencing".(1)
(b)Describe how siRNA brings about the silencing of a target gene after transcription.(4)
(c)Suggest how siRNA technology could, in principle, be used to treat a cancer caused by overexpression of an oncogene.(2)
(Total for Question 6 is 7 marks)
7
Polymerase chain reaction (PCR) is used to amplify a 1.2 kb fragment. Assume perfect doubling each cycle, but primer-dimer and inefficiencies reduce per-cycle efficiency to 90% effective doubling (i.e. multiply by 1.9 each cycle).
(a)Starting from a single copy of the target, write an expression for the number of copies after n cycles with 90% efficiency per cycle.(2)
(b)Calculate the number of copies after 30 cycles. Give your answer in scientific notation to 3 significant figures.(4)
(Total for Question 7 is 6 marks)
8
DNA methylation of a promoter region is measured before and after treatment with a drug. At baseline methylation fraction averaged over the promoter is 0.62 with standard error 0.03 (n = 6). After treatment average methylation fraction is 0.41 with standard error 0.02 (n = 6).
(a)Calculate the percent decrease in mean methylation after treatment (use (baseline - treated)/baseline x 100). Give your answer to 2 significant figures.(2)
(b)Using the standard errors given, calculate the standard error of the difference in means assuming independent samples (SEdiff = √SE12 + SE22). Give your answer to 2 significant figures.(2)
(c)State whether the change in methylation is likely to be statistically significant at approximately the 95% level by comparing the difference in means to twice the SEdiff. Show your comparison and conclusion.(2)
(Total for Question 8 is 6 marks)
9
A western blot experiment measures protein A expression relative to a housekeeping protein H. Densitometry yields integrated intensity for protein A and H for three biological replicates in control and treated cells as below.
(a)Calculate normalised A/H for each replicate and the mean normalised expression for control. Give mean to 3 significant figures.(3)
(b)Calculate mean normalised expression for treated samples to 3 significant figures.(2)
(c)Calculate the percent expression in treated relative to control (treated/control x100) to 2 significant figures.(1)
(Total for Question 9 is 6 marks)
10
The table shows the percentage of tumour samples found to contain a mutation in the p53 tumour suppressor gene, for four types of cancer.
Cancer type: percentage of tumours with p53 mutation
Colorectal: 50%
Lung: 65%
Breast: 30%
Ovarian: 80%
(a)Identify the cancer type with the lowest proportion of tumours showing a p53 gene mutation, and suggest one other way, apart from mutation of the p53 gene itself, by which loss of p53 function could occur in these tumours.(2)
(b)Explain why a mutation that inactivates p53 is more likely to contribute to cancer if it occurs in a body cell that goes on to divide many times, compared with an identical mutation in a cell that rarely divides.(2)
(c)The p53 protein acts as a transcription factor. Explain how a mutation affecting only the DNA-binding domain of p53 (leaving its activation domain unaffected) could still result in complete loss of its tumour-suppressing function.(2)
(Total for Question 10 is 6 marks)
11
The human genome contains approximately 3.2 x 109 base pairs but only about 20 000 protein-coding genes, whereas the human proteome is estimated to contain over 100 000 different proteins.
(a)Protein-coding sequences make up approximately 1.5% of the human genome. Assuming this coding DNA is divided evenly between the 20 000 protein-coding genes, calculate the average number of base pairs of coding DNA per gene.(3)
(b)Using the information given, explain how the number of different proteins in the human proteome (over 100 000) can be greater than the number of protein-coding genes (20 000).(3)
(Total for Question 11 is 6 marks)
12
Somatic (non-germ-line) gene therapy has been trialled as a treatment for cystic fibrosis, an inherited genetic disorder affecting the lungs. Discuss why gene therapy of this type may not provide a permanent cure for the disorder.
(Total for Question 12 is 6 marks)
13
Explain, with reference to proto-oncogenes, tumour suppressor genes and epigenetic control of gene expression, how abnormal DNA methylation patterns can contribute to the development of a tumour.
(Total for Question 13 is 6 marks)
14
A biotechnology company wants to produce recombinant bacteria that express a human gene. The gene is inserted into a bacterial plasmid that carries a gene for ampicillin resistance and a separate gene for tetracycline resistance.
(a)Name the type of enzyme used to cut both the human gene and the plasmid, and describe the type of cut it produces.(2)
(b)Explain why the same restriction enzyme must be used to cut both the human gene fragment and the plasmid vector.(2)
(c)Name the enzyme used to permanently join the human gene into the cut plasmid, and state the type of bond it forms.(2)
(d)The human gene is inserted into the middle of the tetracycline resistance gene, disrupting it. Explain how replica plating on ampicillin-containing and tetracycline-containing agar plates could be used to identify bacterial colonies that have taken up a recombinant plasmid containing the human gene.(4)
(Total for Question 14 is 10 marks)
15
Grace Adeyemi has a family history of breast cancer and undergoes genetic screening using a labelled DNA probe designed to be complementary to a known mutant allele of the BRCA1 gene, a tumour suppressor gene.
(a)Describe how the labelled DNA probe could be used to determine whether Grace's DNA sample contains the mutant BRCA1 allele.(4)
(b)Explain why the DNA probe must be single-stranded.(1)
(c)Grace is found to carry one copy of the mutant BRCA1 allele. Using the "two-hit hypothesis" of tumour suppressor gene function, explain why this greatly increases, but does not guarantee, her risk of developing breast cancer.(3)
(Total for Question 15 is 8 marks)
16
Synoptic scenario. A signalling pathway in hepatocytes regulates expression of enzyme CYPZ which metabolises a drug. A membrane receptor activation leads to phosphorylation cascade, nuclear translocation of transcription factor TF-Z and increased CYPZ transcription. A loss-of-function mutation in the phosphatase P reduces dephosphorylation of the kinase in the cascade, increasing its active time. You are provided with the following experimental observations from hepatocyte cultures:
- Wild-type baseline CYPZ mRNA: 400 arbitrary units (AU).
- After hormone stimulus, wild-type CYPZ mRNA increases to 1600 AU at 2 hours, then returns to 450 AU at 8 hours.
- In P loss-of-function mutant, baseline CYPZ mRNA is 600 AU; after same stimulus CYPZ mRNA increases to 3200 AU at 2 hours and is 1800 AU at 8 hours.
- Drug clearance in mice is proportional to CYPZ activity; in wild-type clearance rate doubles transiently after hormone and returns close to baseline; in mutant mice clearance increases fourfold and remains elevated for longer.
(a)Explain, with reference to phosphorylation state and TF-Z dynamics, why the P loss-of-function mutant has higher baseline CYPZ mRNA than wild-type.(4)
(b)Calculate the fold induction at 2 hours in wild-type and mutant cells (use stimulated level / baseline). Give answers to 2 significant figures.(4)
(c)Using the 8 hour values, calculate the percent remaining of the peak (2 hour) CYPZ mRNA at 8 hours for wild-type and mutant. Give answers to 3 significant figures.(4)
(d)Propose a simple kinetic explanation, using rates of TF-Z nuclear import and removal, for why the mutant shows both greater peak induction and slower return toward baseline. Use labelled rate terms in your answer.(8)
(e)Considering the drug clearance observations in mice, evaluate the likely clinical consequence of P loss-of-function for dosing of the drug metabolised by CYPZ. Include at least two distinct consequences and a brief suggestion for therapeutic monitoring or dose adjustment.(11)
(Total for Question 16 is 31 marks)
17
Explain how the lac operon allows E. coli to produce enzymes for lactose metabolism only when lactose is present. In your answer include the roles of the repressor protein, the operator, and allolactose. You should make the biological mechanism clear and concise.
(Total for Question 17 is 6 marks)
Mark scheme · 1.8 The Control of Gene Expression

Question 1

  • (a) B caoB1
  • (a) Answer: B) Silent mutation
  • (b) a deletion causes a frameshift: the reading frame (grouping into triplets/codons) is shifted from the point of the mutation onwards oeB1
  • (b) every subsequent codon is changed, which may alter every amino acid after the mutation and/or create a premature stop codon oeB1
  • (b) a substitution only ever affects one triplet/codon, so at most only one amino acid changes, and due to the degenerate code it may not change the amino acid (and therefore the protein) at all oeB1
  • (b) Answer: A deletion shifts the reading frame so that every codon after the mutation is altered, whereas a substitution changes at most one codon/amino acid and, because the code is degenerate, may have no effect at all.
  • (c) introns do not code for amino acids and are removed (spliced out) from the pre-mRNA before translation, so a mutation there does not appear in the mature mRNA/protein oeB1
  • (c) Answer: Introns are removed by splicing before translation, so a mutation within an intron is not present in the mature mRNA and does not affect the protein.

Question 2

  • (a) missense: single base change that alters a codon so it codes for a different amino acid oeB1
  • (a) nonsense: mutation that changes a codon to a stop codon, causing premature termination of translation oeB1
  • (a) Answer: Missense: a single base change that alters a codon so a different amino acid is incorporated. Nonsense: a mutation that converts a codon to a stop codon, causing premature termination.
  • (b) calculate number of complete codons before stop: codons = floor((601 - 1)/3) + 1? or simpler: nucleotide position 601 is in codon number 201, oeM1
  • (b) truncated protein length = 200 amino acids (if stop at codon 201, only 200 full amino acids before stop), caoA1
  • (b) Answer: 200 amino acids

Question 3

  • repressible operons are usually on by default and turned off by the corepressor binding to repressor (example: trp operon), oeB1
  • inducible operons are usually off by default and turned on by an inducer binding to repressor or activator (example: lac operon), oeB1
  • mechanism difference: repressible uses negative feedback when end product high; inducible responds to presence of substrate to allow expressionB1
  • functional consequence: repressible prevents wasteful synthesis when product abundant; inducible allows rapid response to available substrateB1
  • Answer: Repressible operons are usually active and shut down when a corepressor binds the repressor (negative feedback); inducible operons are usually inactive and activated when an inducer prevents repressor binding or recruits activator. Repressible saves resources when product abundant; inducible allows expression only when substrate present.

Question 4

  • (a) heritable changes in gene function/expression that do not involve a change to the base/nucleotide sequence of DNA oeB1
  • (a) Answer: Epigenetics is the study of heritable changes in gene expression that occur without any change to the base sequence of DNA.
  • (b) methyl groups are added to cytosine bases in the DNA, often in the promoter region of a gene oeB1
  • (b) increased methylation physically prevents transcription factors and/or RNA polymerase from binding to the DNA, and/or attracts proteins that cause the chromatin to condense (heterochromatin formation) oeB1
  • (b) transcription of the gene is inhibited/prevented, so no mRNA (and therefore no protein) is produced from that gene oeB1
  • (b) Answer: Methyl groups added to cytosine bases (often in the promoter) block transcription factor/RNA polymerase binding and can condense chromatin structure, preventing transcription of the gene.
  • (c) acetyl groups added to histone proteins reduce the overall positive charge on the histones oeM1
  • (c) this reduces the strength of the (electrostatic/ionic) association between the (negatively charged) DNA and the histones oeM1
  • (c) chromatin becomes less condensed (more open/euchromatin), making the DNA more accessible to transcription factors/RNA polymerase, increasing the rate of transcription oeA1
  • (c) Answer: Acetylation reduces the positive charge on histones, loosening the DNA-histone association so chromatin becomes less condensed; this makes the gene more accessible to transcription factors/RNA polymerase, increasing transcription.
  • (d) different patterns of DNA methylation and/or histone modification are established in different cell lineages during development, permanently switching off genes not needed in that cell type oeB1
  • (d) only the genes needed for a particular cell's specialised function remain able to be transcribed/expressed, so cells with the same genome develop different structures and functions oeB1
  • (d) Answer: Different epigenetic marks (methylation/histone modification patterns) are established in different cell lineages, permanently silencing genes not needed for that cell's role, so only a subset of genes remains expressed, producing specialised cells from an identical genome.

Question 5

  • (a) DNA fragments are negatively charged (due to phosphate groups) and are loaded into wells in an agarose gel; a (direct) electric current is applied across the gel oeB1
  • (a) fragments move towards the positive electrode (anode); smaller fragments move further/faster through the pores of the gel than larger fragments in a given time, separating the fragments by size oeB1
  • (a) Answer: DNA fragments, being negatively charged, migrate towards the anode when a current is applied; smaller fragments move further through the gel than larger fragments in the same time, separating them by size.
  • (b) correct substitution: gradient = (log10(100) - log10(1000)) / (52 - 18) = (2 - 3) / 34 shownM1
  • (b) gradient = -1/34 = -0.0294 (3 sf) csoA1
  • (b) Answer: -0.0294 log10(bp) per mm
  • (c) correct intercept found: c = 3 - (-0.0294 x 18) = 3.53 (3 sf) oe (or equivalent method using either calibration point)M1
  • (c) log10(size) = (-0.0294 x 40) + 3.53 = 2.35 (3 sf) shownM1
  • (c) size = 102.35 = 225 bp (awrt 220-230 bp) caoA1
  • (c) Answer: Approximately 225 bp
  • (d) the same restriction enzyme cuts DNA at the same specific (recognition) base sequence in both samples oeB1
  • (d) this produces comparable/corresponding fragments in each sample, so differences in the resulting banding patterns reflect real differences in the DNA sequence between the samples, allowing valid comparison oeB1
  • (d) Answer: Using the same restriction enzyme ensures both samples are cut at the same recognition sequences, producing comparable fragments so that any differences in the banding pattern are due to genuine sequence differences between the samples.

Question 6

  • (a) the prevention/blocking of the expression of a gene, so that no functional protein is produced even though the gene is present in the genome oeB1
  • (a) Answer: Gene silencing is the prevention of expression of a gene, so no (functional) protein is produced even though the gene is present.
  • (b) double-stranded RNA is cut into short fragments (siRNA) by an enzyme oeB1
  • (b) the two siRNA strands separate; one strand associates with a protein complex (RISC) oeB1
  • (b) the siRNA-protein complex binds to a complementary base sequence on the target mRNA (by complementary base pairing) oeB1
  • (b) this leads to the target mRNA being cut/degraded, so it cannot be translated and no (functional) protein is produced from that gene oeB1
  • (b) Answer: Double-stranded RNA is cleaved into siRNA fragments; one strand binds a protein complex which then binds, by complementary base pairing, to matching mRNA; this causes the mRNA to be degraded so it cannot be translated, silencing the gene.
  • (c) an siRNA could be designed with a base sequence complementary to the mRNA transcribed from the oncogene oeM1
  • (c) this would lead to degradation of the oncogene mRNA, preventing/reducing translation and therefore production of the (growth-stimulating) protein, reducing the rate of (uncontrolled) cell division oeA1
  • (c) Answer: A complementary siRNA could be designed to target the oncogene's mRNA, causing its degradation so the growth-stimulating protein is not translated, reducing the rate of cell division.

Question 7

  • (a) recognise per-cycle factor is 1.9 and expression is N = 1 x (1.9)n or equivalentM1
  • (a) N = (1.9)n, caoA1
  • (a) Answer: N = (1.9)n copies
  • (b) evaluate (1.9)30 correctly or using log, oeM1
  • (b) convert to scientific notation correctlyM1
  • (b) answer 2.30 x 108 (3 s.f.)A1
  • (b) unitless count or 'copies' accepted, caoA1
  • (b) Answer: 2.30 x 108 copies

Question 8

  • (a) substitute percent decrease = (0.62 - 0.41)/0.62 x100M1
  • (a) 34% (2 s.f.), caoA1
  • (a) Answer: 34%
  • (b) substitute SEdiff = √0.032 + 0.022M1
  • (b) 0.036 (2 s.f.)A1
  • (b) Answer: 0.036
  • (c) calculate difference = 0.21 and twice SEdiff = 0.072, oeM1
  • (c) 0.21 >> 0.072 so change is likely statistically significant at about 95% level, caoA1
  • (c) Answer: Difference 0.21 > 2 x SEdiff 0.072, so likely statistically significant at about 95% level.

Question 9

  • (a) calculate replicate normalisations: 1200/800=1.5; 1350/900=1.5; 1280/850=1.50588...M1
  • (a) calculate mean = (1.5 + 1.5 + 1.505882)/3M1
  • (a) mean control = 1.50 (3 s.f.), caoA1
  • (a) Answer: Mean normalised control = 1.50
  • (b) calculate treated normalisations: 760/820=0.92683; 690/810=0.85185; 720/830=0.86747M1
  • (b) mean treated = 0.882 (3 s.f.), caoA1
  • (b) Answer: Mean normalised treated = 0.882
  • (c) 59% (2 s.f.), caoA1
  • (c) Answer: 59%

Question 10

  • (a) breast (cancer), 30% caoB1
  • (a) epigenetic silencing of p53, e.g. hypermethylation of the p53 gene's promoter, reducing/preventing its transcription (accept: increased degradation of the p53 protein, or mutation in a gene that regulates p53 activity) oeB1
  • (a) Answer: Breast cancer (30%); loss of function could occur through epigenetic silencing, e.g. hypermethylation of the p53 promoter reducing its transcription.
  • (b) without functional p53, cells with damaged DNA are not repaired and/or are not directed to undergo apoptosis, so further mutations are not eliminated oeM1
  • (b) a cell that divides many times has many more opportunities to accumulate the additional mutations (e.g. in oncogenes) needed for cancer to develop, whereas a cell that rarely divides has few such opportunities oeA1
  • (b) Answer: Loss of p53 means damaged cells are not repaired or removed by apoptosis, so mutations accumulate; a frequently dividing cell has many more opportunities to build up the further mutations needed for cancer than a cell that rarely divides.
  • (c) if the tertiary structure of the DNA-binding domain is altered, p53 can no longer bind to the specific target DNA sequence(s)/promoters of the genes it normally regulates oeM1
  • (c) transcription of these target genes (e.g. those causing cell cycle arrest or apoptosis) is not activated, regardless of a functional activation domain, so the tumour-suppressing effect is lost oeA1
  • (c) Answer: A changed DNA-binding domain prevents p53 from binding to its target gene promoters at all, so those genes (e.g. controlling cell cycle arrest or apoptosis) cannot be activated, even though the activation domain itself still works, resulting in complete loss of function.

Question 11

  • (a) total coding DNA = 1.5% x 3.2 x 109 = 4.8 x 107 (bp) shownM1
  • (a) 4.8 x 107 / 20 000 shownM1
  • (a) = 2400 bp (per gene) caoA1
  • (a) Answer: 2400 bp per gene
  • (b) alternative splicing of pre-mRNA means a single gene's exons can be joined in different combinations, producing more than one mRNA (and therefore more than one polypeptide) from the same gene oeB1
  • (b) post-translational modification (e.g. cleavage of a polypeptide, or addition of chemical groups) of a single polypeptide can produce more than one distinct functional protein oeB1
  • (b) as a result, the total number of distinct proteins in the proteome can be much greater than the number of protein-coding genes in the genome oeB1
  • (b) Answer: Alternative splicing allows one gene to produce several different mRNAs/polypeptides, and post-translational modification can convert a single polypeptide into more than one functional protein, so the proteome contains far more distinct proteins than there are protein-coding genes.

Question 12

  • Level 3 A detailed, coherent discussion that identifies and explains at least two well-developed reasons why somatic gene therapy is unlikely to be permanent (e.g. finite cell lifespan requiring repeat treatment, and either delivery/immune response difficulties or the restriction to somatic rather than germ-line cells), with clear scientific reasoning throughout.5-6
  • Level 2 The answer identifies at least one valid reason (e.g. treated cells are eventually replaced, or delivery of the vector is difficult) with some explanation, but the discussion lacks detail, or only one reason is meaningfully developed.3-4
  • Level 1 Basic or isolated statements, such as "the treatment might not work" or "cells die", with little scientific explanation of why the effect is not permanent.1-2
  • Level 0 No relevant content.0
  • Indicative content:
    • Somatic gene therapy only alters the cells that are directly treated (e.g. lung epithelial cells); it does not affect the patient's egg or sperm cells (germ-line cells), so the effect is not passed on to any offspring and the patient's own reproductive cells still carry the faulty allele.
    • Cells lining the lungs are naturally replaced on a regular basis (a limited/finite lifespan); as treated cells die and are replaced by new, untreated cells that still carry the faulty allele, the beneficial effect of the therapy is gradually lost.
    • As a result, treatment would need to be repeated at intervals throughout the patient's life to maintain any benefit, rather than providing a single, permanent cure.
    • It can be difficult to deliver the vector (e.g. a modified virus or a liposome) to a sufficiently large number of cells throughout the affected tissue (e.g. deep into the lungs) for the treatment to have a significant, lasting clinical effect.
    • The patient's immune system may recognise and destroy the vector (particularly a viral vector) after repeated exposure, reducing the effectiveness of, or triggering an immune response to, subsequent treatments.
    • There is a risk that the inserted gene integrates into the host genome at a random position, potentially disrupting another functional gene (e.g. a tumour suppressor gene or a proto-oncogene), which is a further safety concern with repeated treatment.
    • Germ-line gene therapy, which could in principle produce a permanent, heritable cure, is not currently permitted in humans for ethical and safety reasons, so only the less permanent somatic approach can legally be used.

Question 13

  • Level 3 A detailed and coherent explanation that correctly links hypomethylation of a proto-oncogene (or its promoter) to increased expression and uncontrolled cell division, AND hypermethylation of a tumour suppressor gene promoter to loss of its inhibitory/apoptotic function, with a clear overall link to tumour formation. Scientific terminology is used accurately throughout.5-6
  • Level 2 The answer explains how altered methylation affects transcription/gene expression and refers to either proto-oncogenes or tumour suppressor genes (or both, with limited detail), with some link to uncontrolled cell division, but the explanation of one or both mechanisms is incomplete.3-4
  • Level 1 Basic or isolated statements, such as "methylation switches genes off" or "mutations cause cancer", with little or no explanation of the mechanism linking methylation to gene expression or to cancer.1-2
  • Level 0 No relevant content.0
  • Indicative content:
    • Proto-oncogenes normally code for proteins that stimulate cell division (e.g. growth factors or their receptors), and are usually expressed at controlled/low levels.
    • Hypomethylation (reduced methylation) of a proto-oncogene's promoter increases the rate of transcription, so more growth-stimulating protein is produced.
    • This leads to an increased rate of cell division, contributing to a tumour if uncontrolled (the proto-oncogene is effectively behaving like an oncogene).
    • Tumour suppressor genes normally code for proteins that inhibit cell division, repair damaged DNA, or trigger apoptosis (e.g. p53).
    • Hypermethylation (increased methylation) of a tumour suppressor gene's promoter silences the gene, reducing or preventing its transcription.
    • Less (or no) functional tumour suppressor protein is produced, so cell division is not inhibited and/or damaged cells are not directed to undergo apoptosis.
    • The combined effect of proto-oncogene activation and tumour suppressor gene silencing removes the normal controls on the cell cycle, allowing uncontrolled mitosis/cell division and the growth of a tumour.
    • Because methylation patterns do not change the DNA base sequence, they can be copied to daughter cells during DNA replication/mitosis, so the abnormal gene expression pattern (and increased division rate) can persist and spread through a cell population.

Question 14

  • (a) restriction endonuclease (enzyme) oeB1
  • (a) produces a staggered cut, leaving short single-stranded overhangs ("sticky ends") with exposed, unpaired bases oeB1
  • (a) Answer: A restriction endonuclease, which produces a staggered cut leaving single-stranded "sticky end" overhangs.
  • (b) the same restriction enzyme always cuts at the same recognition sequence, producing complementary/identical sticky ends (base sequences) on both the gene and the plasmid oeM1
  • (b) the exposed bases on the gene fragment can then form complementary base pairs (hydrogen bonds) with the exposed bases on the cut plasmid, allowing the gene to be inserted oeA1
  • (b) Answer: The same restriction enzyme produces complementary sticky ends on both the gene fragment and the plasmid, allowing complementary base pairing between them so the gene can be inserted into the plasmid.
  • (c) DNA ligaseB1
  • (c) (covalent) phosphodiester bond(s) in the sugar-phosphate backbone oeB1
  • (c) Answer: DNA ligase, which forms covalent phosphodiester bonds in the sugar-phosphate backbone.
  • (d) bacteria are first grown/spread on agar containing ampicillin; only bacteria that have taken up a plasmid (recombinant or non-recombinant) are resistant to ampicillin and can grow oeM1
  • (d) colonies are replica plated (transferred in the same relative position) onto agar containing tetracycline oeM1
  • (d) bacteria containing a recombinant plasmid have a disrupted tetracycline resistance gene, so they cannot grow/are killed on the tetracycline plate oeM1
  • (d) the two plates are compared: colonies present on the ampicillin plate but absent from the corresponding position on the tetracycline plate must contain the recombinant plasmid with the human gene oeA1
  • (d) Answer: Colonies are first selected on ampicillin (any transformed bacteria grow); replica plating onto tetracycline shows that only non-recombinant transformed bacteria (with an intact tetracycline gene) grow, so colonies present on ampicillin but absent on tetracycline, in the same position, contain the recombinant plasmid with the inserted gene.

Question 15

  • (a) Grace's (double-stranded) DNA sample is denatured (e.g. by heating or using alkali) to separate it into single strands oeB1
  • (a) the single-stranded, labelled probe, with a base sequence complementary to the mutant allele, is added to the sample oeB1
  • (a) if the mutant allele is present, the probe binds/hybridises to it by complementary base pairing (forming hydrogen bonds) oeB1
  • (a) unbound probe is washed away; the presence of the label (e.g. fluorescence, or exposure of photographic film for a radioactive label) shows that the mutant allele is present oeB1
  • (a) Answer: The DNA sample is denatured to single strands; a labelled, single-stranded probe complementary to the mutant allele is added and hybridises to it if present by complementary base pairing; excess probe is washed off and detection of the label confirms the mutant allele is present.
  • (b) so that its bases are free/exposed to form complementary base pairs (hydrogen bonds) with the complementary single strand of the sample DNA oeB1
  • (b) Answer: The probe must be single-stranded so its bases are available to hybridise (form complementary base pairs) with a matching single strand in the sample.
  • (c) BRCA1 is a tumour suppressor gene; normally both alleles must be inactivated ("two hits") before its function (e.g. DNA repair/inhibiting cell division) is lost oeM1
  • (c) Grace has already inherited one non-functional/mutant allele in every cell (the "first hit"), so she only needs a second, somatic mutation to inactivate her one remaining normal allele oeM1
  • (c) the risk of cancer is greatly increased because only one further (random) mutation is needed, but it is not certain because this second "hit" is a chance event that may never occur in a particular cell oeA1
  • (c) Answer: Because both copies of a tumour suppressor gene must normally be inactivated for its function to be lost, and Grace already carries one non-functional allele in every cell, she only needs a single further somatic mutation in the remaining normal allele; this makes cancer much more likely but not certain, since that second mutation is a random event that may or may not occur.

Question 16

  • (a) state that phosphatase P normally dephosphorylates an active kinase, limiting its active timeM1
  • (a) loss of P increases steady-state level of phosphorylated active kinaseM1
  • (a) more active kinase leads to increased phosphorylation and nuclear translocation of TF-Z even without stimulusM1
  • (a) this causes higher baseline transcription of CYPZ in the mutant, caoA1
  • (a) Answer: Without P activity the kinase remains more phosphorylated and active, increasing TF-Z phosphorylation and nuclear localisation even in absence of stimulus; increased TF-Z in nucleus enhances basal CYPZ transcription, explaining higher baseline mRNA.
  • (b) wild-type fold = 1600/400 = 4M1
  • (b) mutant fold = 3200/600 = 5.333...M1
  • (b) wild-type 4.0 (2 s.f.)A1
  • (b) mutant 5.3 (2 s.f.), caoA1
  • (b) Answer: Wild-type 4.0; Mutant 5.3
  • (c) wild-type percent = 450/1600 x100M1
  • (c) mutant percent = 1800/3200 x100M1
  • (c) wild-type = 28.1% (3 s.f.)A1
  • (c) mutant = 56.3% (3 s.f.), caoA1
  • (c) Answer: Wild-type 28.1%; Mutant 56.3%
  • (d) define rate of TF-Z nuclear import as kin and rate of TF-Z removal (export or dephosphorylation) as koutM1
  • (d) state that phosphatase P loss reduces kout or increases effective kin/kout ratioM1
  • (d) higher kin/kout leads to larger steady-state nuclear TF-Z during stimulus hence greater transcriptional activation and larger peakM1
  • (d) reduced kout slows removal of TF-Z from nucleus after stimulus, causing slower decline of transcription and higher remaining mRNA at 8 hoursM1
  • (d) link to mRNA dynamics: transcription rate is proportional to nuclear TF-Z, and mRNA decay means prolonged high transcription sustains higher mRNAM1
  • (d) mention that kinase dephosphorylation being slower increases active kinase lifetime, effectively decreasing kout or increasing TF-Z phosphorylation rateM1
  • (d) explain qualitative prediction: mutant has both increased peak and prolonged tail in mRNA timecourseM1
  • (d) coherent kinetic chain described linking molecular rates to observed mRNA timecourse, caoA1
  • (d) Answer: Let kin be TF-Z nuclear import rate and kout its removal rate. Loss of P reduces kout (or increases effective phosphorylation-driven import), increasing kin/kout so more TF-Z accumulates in nucleus during stimulus giving larger peak transcription. Slower kout delays TF-Z removal after stimulus so transcription stays elevated longer; with mRNA decay this produces a slower return of CYPZ mRNA to baseline.
  • (e) state that increased CYPZ expression increases metabolic clearance of the drugM1
  • (e) note that mutant shows fourfold increase in clearance and prolonged elevation, so drug exposure (AUC) will be substantially reducedM1
  • (e) consequence 1: reduced therapeutic efficacy at standard dose because plasma concentration falls fasterM1
  • (e) consequence 2: need for higher or more frequent dosing to maintain therapeutic levels, with risk of variable responseM1
  • (e) risk: induction can persist so accumulation of active metabolites or production of toxic metabolites could occur; mention possibilityM1
  • (e) suggest monitoring plasma drug concentration or pharmacodynamic markers to guide dose adjustmentM1
  • (e) suggest alternative strategy: use drugs not metabolised by CYPZ or co-administer CYPZ inhibitor cautiouslyM1
  • (e) comment on safety: faster clearance might require higher dose but also increases risk if the drug has active metabolites or narrow therapeutic indexM1
  • (e) state that genetic testing for P loss-of-function could inform personalised dosingM1
  • (e) weigh benefits and harms and conclude that increased dosing may be needed but must be guided by monitoring, caoM1
  • (e) clear, balanced evaluation with monitoring and alternative suggestions earning full creditA1
  • (e) Answer: Likely consequences: CYPZ induction increases clearance so standard dosing will give lower drug exposure and reduced efficacy; sustained induction in mutant causes prolonged low exposure necessitating higher or more frequent dosing. Risks include altered metabolite profiles and toxicity if metabolites are active. Recommended actions: therapeutic drug monitoring of plasma concentrations or PD markers, consider genotype-guided dosing, or choose alternative drugs not metabolised by CYPZ. Any dose increase should be cautious and guided by monitoring.

Question 17

  • Level 3 Detailed explanation that links repressor binding, allolactose binding, operator accessibility and resulting transcription with clear causal statements and correct terminology.5-6
  • Level 2 Reasonable explanation that includes most key points but lacks some causal clarity or precise terminology.3-4
  • Level 1 Simple statement that mentions either repressor or inducer without linking to control of transcription.1-2
  • Indicative content:
    • In absence of lactose the lac repressor binds to the operator preventing RNA polymerase from transcribing lac genes; this stops production of lactose-metabolising enzymes.
    • Allolactose, an isomer of lactose formed at low rate, acts as an inducer by binding to the repressor and causing a conformational change.
    • Binding of allolactose reduces the repressor affinity for the operator so it dissociates, freeing the promoter for RNA polymerase binding.
    • RNA polymerase can then transcribe the lacZYA genes producing beta-galactosidase, permease and transacetylase; gene expression increases only when inducer is present.
    • Details of negative control, reversible binding, and the energetic advantage of expressing enzymes only when substrate is available.

Mark your answers

Check answers without an account. Some answers can be checked automatically; use the mark scheme to mark the rest.

Question 1(a)

1 mark
Choose an answer

Question 1(b)

3 marks
Did your answer earn the marks?

Question 1(c)

1 mark
Did your answer earn the marks?

Question 2

4 marks
Did your answer earn the marks?

Question 3

4 marks
Did your answer earn the marks?

Question 4

9 marks
Did your answer earn the marks?

Question 5

9 marks
Did your answer earn the marks?

Question 6

7 marks
Did your answer earn the marks?

Question 7

6 marks
Did your answer earn the marks?

Question 8

6 marks
Did your answer earn the marks?

Question 9

6 marks
Did your answer earn the marks?

Question 10

6 marks
Did your answer earn the marks?

Question 11

6 marks
Did your answer earn the marks?

Question 12

6 marks
Did your answer earn the marks?

Question 13

6 marks
Did your answer earn the marks?

Question 14

10 marks
Did your answer earn the marks?

Question 15

8 marks
Did your answer earn the marks?

Question 16

31 marks
Did your answer earn the marks?

Question 17

6 marks
Did your answer earn the marks?
Mark my answers

Worksheets are written for Revision Library and come with a full mark scheme; a few English packs quote an out-of-copyright text, and name it on the page. Exam board names and specification codes say which qualification a pack suits: we are not affiliated with, endorsed by or approved by any exam board, and no past-paper question is reproduced here. Rights queries: hello@revisionlibrary.co.uk